儿童表观遗传修饰药物开发共识:BET抑制剂的优先开发策略
该共识基于生物学和临床前数据,明确BET抑制剂在儿童恶性肿瘤中的三个潜在应用方向:NUT癌、MYC/MYCN驱动肿瘤及融合驱动肿瘤。由于至少10种BET抑制剂在研而儿童患者有限,会议建议优先开发BMS-986158并等待其首个儿童试验结果,同时关注BDII选择性、CNS穿透性及双靶点抑制剂。
要点
- BET抑制剂在儿童中的优先适应症为NUT癌,需全球可及性。
- 其他pan-BET抑制剂的儿童开发应等待BMS-986158首个儿童试验结果。
- BDII选择性、CNS穿透性及BET/p300双靶点抑制剂值得进一步临床前研究。
核心结论
- 科学上不合理且不可行同时对所有pan-BET抑制剂开展儿童早期临床试验。
- NUT癌患者存在BET抑制剂的临床需求,开发与监管路径应涵盖儿童和青少年及成人。
- 其他pan-BET抑制剂的儿童开发应等待BMS-986158首个儿童临床试验结果,除非特定药物有强有力理由。
研究设计与样本
- 基于生物学和临床前数据召开共识会议,参与者包括生物制药公司、学术研究者及患者和家庭倡导者。
- 会议目的是就BET抑制剂的开发达成共识,包括优先顺序及其在儿童中的具体作用。
主要发现
- BET抑制剂自2012年起在成人中开展临床试验,首个儿童研究(BMS-986158)于2019年才开放。
- 大多数pan-BET抑制剂在成人中给药困难,单药抗肿瘤活性有限,且因血小板减少导致治疗窗窄。
- NUT癌由溴结构域融合驱动,部分患者接受BET抑制剂有临床获益的概念验证。
关键数值与推荐
- BET抑制剂在儿童恶性肿瘤中至少有三个潜在作用:NUT癌、MYC/MYCN驱动癌症和融合驱动恶性肿瘤。
- 目前至少有10种BET抑制剂在研发中。
- BET抑制剂在成人临床试验中自2012年开始,首个儿童研究BMS-986158于2019年开放。
临床怎么用
- NUT癌患者应获得BET抑制剂的全球可及性,开发路径包括儿童和青少年及成人。
- 其他pan-BET抑制剂的儿童临床开发应等待BMS-986158首个儿童试验结果。
- 当某类药物有强机制理由或临床前活性时,应优先在儿童中早期临床评估并嵌入相关研究。
局限性
- 临床前数据虽大量但并非普遍支持BET抑制剂在所有儿童肿瘤中的应用。
- pan-BET抑制剂单药在成人中抗肿瘤活性有限且治疗窗窄。
- 儿童相关人群有限,难以同时评估所有在研BET抑制剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Based on biology and pre-clinical data, bromodomain and extra-terminal (BET) inhibitors have at least three potential roles in paediatric malignancies: NUT (nuclear protein in testis) carcinomas, MYC/MYCN-driven cancers and fusion-driven malignancies. However, there are now at least 10 BET inhibitors in development, with a limited relevant paediatric population in which to evaluate these medicinal products. Therefore, a meeting was convened with the specific aim to develop a consensus among relevant biopharmaceutical companies, academic researchers, as well as patient and family advocates, about the development of BET inhibitors, including prioritisation and their specific roles in children. Although BET inhibitors have been in clinical trials in adults since 2012, the first-in-child study (BMS-986158) only opened in 2019. In the future, when there is strong mechanistic rationale or pre-clinical activity of a class of medicinal product in paediatrics, early clinical evaluation with embedded correlative studies of a member of the class should be prioritised and rapidly executed in paediatric populations. There is a strong mechanistic and biological rationale to evaluate BET inhibitors in paediatrics, underpinned by substantial, but not universal, pre-clinical data. However, most pan-BET inhibitors have been challenging to administer in adults, since monotherapy results in only modest anti-tumour activity and provides a narrow therapeutic index due to thrombocytopenia. It was concluded that it is neither scientifically justified nor feasible to undertake simultaneously early clinical trials in paediatrics of all pan-BET inhibitors. However, there is a clinical need for global access to BET inhibitors for patients with NUT carcinoma, a very rare malignancy driven by bromodomain fusions, with proof of concept of clinical benefit in a subset of patients treated with BET inhibitors. Development and regulatory pathway in this indication should include children and adolescents as well as adults. Beyond NUT carcinoma, it was proposed that further clinical development of other pan-BET inhibitors in children should await the results of the first paediatric clinical trial of BMS-986158, unless there is compelling rationale based on the specific agent of interest. BDII-selective inhibitors, central nervous system-penetrant BET inhibitors (e.g. CC-90010), and those dual-targeting BET/p300 bromodomain are of particular interest and warrant further pre-clinical investigation. This meeting emphasised the value of a coordinated and integrated strategy to drug development in paediatric oncology. A multi-stakeholder approach with multiple companies developing a consensus with academic investigators early in the development of a class of compounds, and then engaging regulatory agencies would improve efficiency, productivity, conserve resources and maximise potential benefit for children with cancer.
引用
- Pearson AD, DuBois SG, Buenger V, et al. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. Eur J Cancer. 2021. PMID: 33601323. doi:10.1016/j.ejca.2021.01.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。